Genmab A/S (GNMSF) Cash & Equivalents (2018 - 2026)

Genmab A (GNMSF) has 7 years of Cash & Equivalents data on file, last reported at $1.5 billion in Q1 2026.

• Quarterly Cash & Equivalents fell 6.05% year-over-year to $1.5 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 billion (down 6.05% YoY) and the FY2025 annual result came in at $1.7 billion, up 24.28% from the prior year.
• Cash & Equivalents eased to $1.5 billion in Q1 2026, from $1.7 billion in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $2.2 billion in Q4 2023 to a low of $622.0 million in Q2 2024.
• A 4-year average of $1.5 billion and a median of $1.6 billion in 2025 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2024 — Cash & Equivalents tumbled 37.39% — and 2025, when it surged 108.36%.
• Tracing GNMSF's Cash & Equivalents over 4 years: stood at $2.2 billion in 2023, then tumbled by 37.39% to $1.4 billion in 2024, then advanced by 24.28% to $1.7 billion in 2025, then decreased by 11.31% to $1.5 billion in 2026.
• The last three Cash & Equivalents figures came in at $1.5 billion (Q1 2026), $1.7 billion (Q4 2025), and $1.8 billion (Q3 2025), per Business Quant data.